Michael Flood
Overview
Explore the profile of Michael Flood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crabbe M, Flood M, Adams K
Aust N Z J Public Health
. 2024 Mar;
48(3):100135.
PMID: 38508985
Objective: This article aims to explore the extent and nature of Australian young people's pornography exposure and access. Methods: Cross-sectional online survey of 1,985 young Australians aged 15-20 years, nationally...
2.
Ghaziuddin N, McClintock S, Maixner D, Miller L, Husain M, Wachtel L, et al.
J Affect Disord
. 2024 Mar;
356:32-33.
PMID: 38479508
No abstract available.
3.
Chen V, Jones M, Cohen L, Yang W, Bedi J, Mohan H, et al.
Pleura Peritoneum
. 2022 Dec;
7(4):159-167.
PMID: 36560970
Objectives: Small bowel adenocarcinoma (SBA) with peritoneal metastasis (PM) is rare and despite treatment with systemic chemotherapy, the prognosis is poor. However, there is emerging evidence that cytoreductive surgery (CRS)...
4.
Jordan A, Mills K, Sobukonla T, Bredy S, Kelly A, Flood M
Colorectal Dis
. 2022 Jul;
24(12):1550-1555.
PMID: 35881672
Aim: Major depressive disorder is a prominent psychiatric illness in the United States. It has been found to be higher among patients with inflammatory bowel disease. However, few studies have...
5.
Ramsay R, Flood M
Br J Cancer
. 2022 Jul;
127(3):377-378.
PMID: 35831561
Colorectal peritoneal metastases (CRPM) can be resistant to the chemotherapy agent (oxaliplatin) most employed, up until recently, as hyperthermic intraperitoneal chemotherapy (HIPEC). Glutathione-mediated inactivation of oxaliplatin can be substantially reduced...
6.
Sampurno S, Chittleborough T, Dean M, Flood M, Carpinteri S, Roth S, et al.
Ann Surg Oncol
. 2022 Jul;
29(12):7911-7920.
PMID: 35794366
Background: Pre-clinical studies indicate that dry-cold-carbon-dioxide (DC-CO2) insufflation leads to more peritoneal damage, inflammation and hypothermia compared with humidified-warm-CO (HW-CO2). Peritoneum and core temperature in patients undergoing colorectal cancer (CRC)...
7.
Jordan A, Mills K, Sobukonla T, Kelly A, Flood M
Cureus
. 2021 Nov;
13(9):e18387.
PMID: 34729268
Background Inflammatory bowel disease (IBD) and its immunosuppressive therapy alter the body's immune response, predisposing patients to higher infection risk preventable with vaccination. The CDC recommends every adult receive the...
8.
Flood M, Narasimhan V, Wilson K, Lim W, Ramsay R, Michael M, et al.
Ann Surg Oncol
. 2021 Oct;
29(1):47-59.
PMID: 34596795
Background: Patients with locally advanced or metastatic colorectal cancer (CRC) display heterogeneous responses to standard-of-care therapy. Robust preclinical models of malignancy in the form of patient-derived tumor organoids (PDTOs) have...
9.
Flood M, Ramsay R, Heriot A
Ann Surg Oncol
. 2021 Sep;
29(1):60-61.
PMID: 34545532
No abstract available.
10.
Kong J, Flood M, Ramsay R, Warrier S, Heriot A
ANZ J Surg
. 2021 May;
91(5):778-780.
PMID: 33999535
No abstract available.